FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may alter the active pharmaceutical ingredient, manufacturing process or site, formulation, batch size, and container closure system. These modifications can occur in new or generic drug products and often involve multiple changes simultaneously. Each alteration requires careful evaluation before distribution to ensure the drug maintains its identity, strength, quality, purity, potency, safety, and efficacy.

The FDA classifies post-approval changes into three categories: major, moderate, and minor. Major changes substantially impact drug safety or effectiveness and require Prior Approval Supplement before distribution. Moderate changes moderately impact drugs and require a supplement submitted 30 days before distribution. Minor changes have minimal influence and must be reported in the manufacturer's next annual report.

Manufacturing site relocation is classified as a major change because it substantially impacts drug safety and effectiveness. Major changes require a Prior Approval Supplement, meaning the FDA must approve the change before the modified product can be distributed. Manufacturers must thoroughly evaluate how the site change affects the drug's identity, strength, quality, purity, potency, safety, and efficacy.

Moderate changes, such as modifications in the manufacturing process, require submitting a supplement to the FDA. Distribution can occur when the FDA receives the supplement, or manufacturers may distribute 30 days after submission. These changes have moderate potential for adverse effects, so manufacturers must assess their impact on drug quality and formulation and manufacturing process physical attributes before distribution.

Minor changes, such as updating existing code imprints for dosage forms from numeric to alphanumeric, have minimal influence on the drug product. These changes do not require prior FDA approval or a supplement submission. Instead, manufacturers must report minor changes in their next annual report to the FDA, maintaining transparency about all product modifications.

Manufacturers must assess the effects of any post-approval change before distributing a modified drug product because changes can impact the drug's identity, strength, quality, purity, potency, safety, and efficacy. This evaluation determines the change's classification level and the appropriate FDA reporting pathway. Proper assessment ensures the modified product maintains its therapeutic effectiveness and safety profile.

A Prior Approval Supplement is required for major post-approval changes that substantially affect drug safety or effectiveness. Examples include manufacturing site relocation. This supplement requires FDA approval before the manufacturer can distribute the modified drug product. The Prior Approval Supplement process ensures the FDA reviews and authorizes significant changes before they reach patients.